tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Archive for 'Trading News'

PharmaCyte Biotech’s Release Testing Last Critical Event Before Submission of Investigational New Drug Application

PharmaCyte Biotech’s Release Testing Last Critical Event Before Submission of Investigational New Drug Application

Written by Ι Stock Market Media — November 12, 2019

PharmaCyte Biotech (OTCQB: PMCB) has reduced a long list of FDA-required items to just one last important component—release testing—before it can submit an Investigational New Drug application (IND) to the U.S. FDA.  PharmaCyte’s IND application will request permission from the FDA to conduct a Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).  With the FDA’s approval to begin a clinical trial, PharmaCyte’s opportunities for funding improve dramatically.

PharmaCyte has already ...

Read More →
0

GBT Technologies Competing in $4 Trillion AI Market with Disruptive Technology

GBT Technologies Competing in $4 Trillion AI Market with Disruptive Technology

Written by Ι Stock Market Media — November 8, 2019

GBT Technologies, Inc. (OTC PINK: GTCH) has a vast portfolio of intellectual property that spans both the Artificial Intelligence (AI) and Internet of Things (IoT) markets.  But the company’s central focus is on a technology called “Avant! AI”—a technology that could become commonplace in both businesses and households worldwide.  It is the extremely promising potential of Avant! that has GBT Technologies (GBT) ideally positioned to compete in what Gartner, a leading research and ...

Read More →
0

PharmaCyte Biotech to Change Future of Treating Diseases with Validation of Encapsulation Technology in Pancreatic Cancer Trial

PharmaCyte Biotech to Change Future of Treating Diseases with Validation of Encapsulation Technology in Pancreatic Cancer Trial

Written by Ι Stock Market Media — October 28, 2019

PharmaCyte Biotech (OTCQB: PMCB) has a technology that could very well change the way a host of hard-to-treat diseases are treated for the foreseeable future.  The company is closer than ever to its upcoming Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) that could give patients a new lease on life by shrinking their tumors enough so that the tumors can be removed surgically.  It is an outcome that would ...

Read More →
0

PharmaCyte Biotech Closer to Submitting IND with Successful Completion of Clinical Trial Product

PharmaCyte Biotech Closer to Submitting IND with Successful Completion of Clinical Trial Product

Written by Ι Stock Market Media — October 16, 2019

NEW YORK, NY, Oct. 16, 2019 — PharmaCyte Biotech (OTCQB: PMCB) has now moved one step closer to submitting an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) to request a clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) in the United States.  The company has successfully completed the first of two manufacturing runs to produce the clinical trial product (Cell-in-a-Box® capsules) it needs for ...

Read More →
0

Tech Central, Inc. Aggressively Enters CBD Market with CBD Product Line & Opportunity to Create New Brands

Tech Central, Inc. Aggressively Enters CBD Market with CBD Product Line & Opportunity to Create New Brands

Written by Ι Stock Market Media — August 26, 2019

New York, NY — Tech Central, Inc. (OTC Markets: TCHC) entered the CBD market this year (2019) with an aggressive approach that not only included launching its own CBD products, but also includes helping burgeoning businesses build their exclusive CBD brand in the industry as well.

In just a few short months, the company has announced the development of its “CBD Affiliate Marketer” app, launched its “Better Mind CBD” line ...

Read More →
0

Cyber Security 1 Highlighted in New Research Report After Record Highs in Both Quarterly & Annual Revenue Growth

Cyber Security 1 Highlighted in New Research Report After Record Highs in Both Quarterly & Annual Revenue Growth

Written by Ι Stock Market Media — March 27, 2019

Cyber Security 1 (OTCQX: CYBNY) (Nasdaq First North: CYB1), a leading international cyber security firm that provides cyber resilience solutions to an ever-growing list of clients globally, enjoyed record revenue growth in 2018.  The company’s recent financial report highlights what was an impressive 2018 for Cyber Security 1 (CYBER1).  The report states that CYBER1 set records with back-to-back quarters of total quarterly revenue growth and year-over-year total annual revenue growth.

After a ...

Read More →
0
Page 1 of 32 12345...»
ContactUs.com